Pharming (ADR) (PHAR)
Commercializes rare-disease medicines while advancing a mitochondrial-disease program.
Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky
Pharming Group told investors to expect up to $425 million in 2026 revenue. The Company now expects as little as $375 million -- and the stock lost 22% in a single session.
Ratio makes improved bid for Pharos Energy
Ratio Petroleum Energy has raised its recommended offer for Pharos Energy (LSE:PHAR) to 32.8183p per share, trumping a rival bid from Serica Energy PLC (AIM:SQZ) and valuing the company at around £146.4 million. The revised terms comprise 28.8183p in cash plus a 4p special dividend.
Pharming Group N.V. (PHAR) Shareholders Who Lost Money -- Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Law Offices of Howard G. Smith announces an investigation on behalf of Pharming Group N.V. (âPharmingâ or the âCompanyâ) (NASDAQ: [url="]PHAR[/url]) inv
Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR) on behalf of investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON PHARMING GROUP N.V. (PHAR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.What Is The Investigation About? On July 30, 2026, the Company reported second quarter earnings, inc.
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Pharming Group (PHAR)
Pharming Group shares fell 22% on July 30, 2026 after the Company reported a Q2 revenue decline and reduced its full-year 2026 outlook by roughly $30 million. Levi & Korsinsky is investigating potential securities law violations on behalf of PHAR investors Pharming Group shares fell 22% on July 30, 2026 after the Company reported a Q2 revenue decline and reduced its full-year 2026 outlook by roughly $30 million. Levi & Korsinsky is investigating potential securities law violations on behalf of PHAR investors
PHAR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Pharming Group (PHAR)
A 22% single-session drop hit Pharming Group (PHAR) shares today after the Company reported Q2 2026 revenue of $90.2 million -- a 3% year-over-year decline agai
Pharming Group Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Pharming Group (PHAR)
Pharming Group's legacy product RUCONEST posted a 10% year-over-year sales decline in Q2 2026 -- and PHAR shares fell 22% the day it was reported. Levi & Korsinsky is investigating potential securities law violations on behalf of PHAR shareholders.
Pharming Group N.V. (PHAR) Q2 2026 Earnings Call Transcript
Pharming Group N.V. (PHAR) Q2 2026 Earnings Call Transcript
Pharming Group Q2 Earnings Call Highlights
Pharming Group NASDAQ: PHAR reported second-quarter revenue of $90.2 million, down 3% from a year earlier, as growth from its Joenja treatment partly offset lower sales of hereditary angioedema therapy RUCONEST. The company reduced its full-year revenue outlook by $30 million but said it expects RUCONEST sales to stabilize and return to growth during the second half of 2026.
Analysts Set Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Target Price at $38.33
Shares of Pharming Group N.V. Sponsored ADR (NASDAQ: PHAR - Get Free Report) have earned a consensus rating of "Hold" from the five brokerages that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating
Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
If approved, Joenja will be the first approved treatment in the U. S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency Supplemental New Drug Application (sNDA) resubmission seeks approval for 40 mg and 50 mg twice-daily dosingSeparate sNDA for lower weight pediatric patients planned for second half 2026 Leiden, the Netherlands, June 4, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.
Pharming Group Q1 Earnings Call Highlights
Pharming Group NASDAQ: PHAR executives said first-quarter 2026 results reflected an expected decline in RUCONEST revenue tied largely to specialty pharmacy inventory movements and the company's planned exit from certain non-U.S. markets, while Joenja continued to post strong growth and the company advanced regulatory and clinical milestones across its pipeline. Get Pharming Group alerts:Sign UpRUCONEST revenue declined as inventory dynamics played out CEO Fabrice Chouraqui said quarterly revenue fell primarily due to RUCONEST, a decline he said was “largely expected due to inventory drawdown at specialty pharmacy,” which the company previously discussed on its fourth-quarter 2025 call.
Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript
Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript
Short Interest in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Declines By 15.5%
Pharming Group N.V. Sponsored ADR (NASDAQ: PHAR - Get Free Report) saw a large decline in short interest during the month of March. As of March 31st, there was short interest totaling 12,882 shares, a decline of 15.5% from the March 15th total of 15,251 shares. Approximately 0.0% of the company's shares are sold short. Based
Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript
Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. ("Pharming" or the "Company") (NASDAQ: PHAR).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR
NEW YORK, Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. ("Pharming" or the "Company") (NASDAQ: PHAR).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. ("Pharming" or the "Company") (NASDAQ: PHAR).